researchintokyo.com

Japan Market Access

Japan Market Access

  • Home
  • Japan Market Access
    • Coverage Decisions
    • Pricing and Reimbursement
  • Approvals
    • List of New Drugs/Indications Approved in Japan in 2014
  • Services
    • Marketing Authorization
  • Blog
  • About Us
  • Contact Us

Recent Posts

  • Protected:
  • Anti-VEGF Battles: Eylea Overtakes Lucentis in Japan
  • iPS Cell Regenerative Medicine to Rely on Donor Cells in Order to Cut 77% of Costs
  • Plan: Generics to increase from 60% to 80% by 2017
  • Average Nursing Care Premium Breaks Through ¥5000

Protected:

This entry was posted in Uncategorized and tagged CGRP japan approval migraine new drugs on April 12, 2020 by RIT (updated 2158 days ago)

This content is password-protected. To view it, please enter the password below.

Post navigation

  • ← Anti-VEGF Battles: Eylea Overtakes Lucentis in Japan

· © 2026 researchintokyo.com · Designed by Press Customizr · Powered by ·